Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A setting...

Full description

Bibliographic Details
Main Authors:	Allison M Lytle, Harrison C Brown, Na Yoon Paik, Kristopher A Knight, J Fraser Wright, H Trent Spencer, Christopher B Doering
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050116301462

Similar Items

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
by: Harrison C Brown, et al.
Published: (2014-01-01)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
by: Nadia El-Akabawy, et al.
Published: (2020-06-01)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
by: Sajjad Afraz, et al.
Published: (2022-11-01)

Recombinant FVIII: the milestone of modern hemophilia treatment
by: Pier Mannuccio Mannucci
Published: (2020-06-01)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
by: Seema R. Patel, et al.
Published: (2020-04-01)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
by: S. Nguyen, et al.
Published: (2019-01-01)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
by: Cansu Hemşinlioğlu, et al.
Published: (2023-06-01)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
by: Louise H Hooimeijer MD, et al.
Published: (2023-03-01)

Flow Cytometry Evaluation of Blood-Cell-Bound Surface FVIII in Hemophilia A and Thrombosis
by: Anjud Al-Mohannadi, et al.
Published: (2025-01-01)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
by: Daniel P. Hart
Published: (2020-07-01)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
by: Chao Lien Liu, et al.
Published: (2016-06-01)

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A
by: Harrison C. Brown, et al.
Published: (2018-06-01)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
by: Martin Rodriguez, et al.
Published: (2023-07-01)

The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia
by: Yingzi Zhen, et al.
Published: (2024-12-01)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
by: Janine Becker-Gotot, et al.
Published: (2022-11-01)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
by: Yuanhua Cai, et al.
Published: (2020-06-01)

Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice
by: Weiqing Jing, et al.
Published: (2019-10-01)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
by: Marcos V. Ferreira, et al.
Published: (2023-05-01)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022-11-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Oomen, I, et al.
Published: (2024)

Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR-Cas9 mRNA LNPs
by: Chun-Yu Chen, et al.
Published: (2024-12-01)

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression
by: Qizhen Shi, et al.
Published: (2020-01-01)

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
by: Melissa Bou-Jaoudeh, et al.
Published: (2023-01-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Ilja Oomen, et al.
Published: (2024-02-01)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
by: Shuichi Okamoto, et al.
Published: (2019-10-01)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
by: K. Huang, et al.
Published: (2022-06-01)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
by: Ritu M. Ramamurthy, et al.
Published: (2022-12-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group
by: Chozie, Novie Amelia, et al.
Published: (2022)

Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study
by: Mizoguchi Y, et al.
Published: (2025-01-01)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII
by: Devi Gunasekera, et al.
Published: (2023-03-01)

Bioengineering coagulation factors for improved hemophilia treatments : Comment on: the mutation F309S increases FVIII secretion in human cell line
by: Bidossessi Wilfried Hounkpe, et al.

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines
by: Sunil S. Raikar, et al.
Published: (2018-03-01)

QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC
by: L Loureiro, et al.
Published: (2023-10-01)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01)

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity
by: Ruth A. Ettinger, et al.
Published: (2018-02-01)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
by: Christian Lubich, et al.
Published: (2022-10-01)

TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice
by: Dipica Haribhai, et al.
Published: (2016-12-01)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A
by: Dawei Wang, et al.
Published: (2020-04-01)